Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 24 references indexed in Scilit:
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesNew England Journal of Medicine, 2011
- Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle VaccineThe Pediatric Infectious Disease Journal, 2010
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trialThe Lancet, 2009
- Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus‐Like‐Particle VaccineThe Journal of Infectious Diseases, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult WomenPediatrics, 2006
- Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 diseaseVaccine, 2006
- Comparative analysis of two ratesStatistics in Medicine, 1985